PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE

Abstract
Purpose: Little is known about the incidence rate and clinical relevance of prostate cancer in a low prostate specific antigen (PSA) level. In a prospective PSA based screening study we investigate...

This publication has 27 references indexed in Scilit: